FROM PRESS
to presentations

News

FILTER
October 9, 2024
REVALESIO’S INVESTIGATIONAL TREATMENT RNS60 PROTECTS MITOCHONDRIA IN PRECLINICAL MODEL OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
September 17, 2024
REVALESIO’S INVESTIGATIONAL RNS60 EXTENDED SURVIVAL IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN POST-HOC ANALYSIS OF PHASE 2 INVESTIGATOR-SPONSORED TRIAL
February 7, 2024
REVALESIO ANNOUNCES POSITIVE TOPLINE DATA FROM PHASE 2 RESCUE STUDY OF RNS60 IN PATIENTS WITH ACUTE ISCHEMIC STROKE IN LATE-BREAKING ORAL PRESENTATION AT ISC 2024
February 18, 2022
REVALESIO ANNOUNCES THE DESIGN OF RESCUE, A PHASE 2 TRIAL OF RNS60 IN ACUTE ISCHEMIC STROKE, AND THE PRESENTATION OF PRECLINICAL DATA AT THE INTERNATIONAL STROKE CONFERENCE 2022
DECEMBER 7, 2021
PROMISING CLINICAL DATA ON REVALESIO’S RNS60 PRESENTED AT 32ND INTERNATIONAL SYMPOSIUM ON ALS/MND
FEBRUARY 23, 2021
REVALESIO SIGNS AGREEMENT TO DESIGN TRIAL WITH RNS60 FOR THE HEALEY ALS PLATFORM TRIAL
JANUARY 4, 2019
FDA GRANTS REVALESIO FAST TRACK STATUS FOR ALS INVESTIGATIONAL DRUG RNS60
MARCH 6, 2018
RNS60 PROMOTES MYELINATION OF NANOFIBERS BY OLIGODENDROCYTES
SEPTEMBER 20, 2017
FDA GRANTS REVALESIO ORPHAN DRUG STATUS FOR ALS INVESTIGATIONAL DRUG RNS60
DECEMBER 22, 2016
FDA ALLOWS REVALESIO’S INVESTIGATIONAL NEW DRUG APPLICATION TO STUDY RNS60 IN ALS
DECEMBER 2, 2016
ALS ACT AWARDS 1MM USD GRANT TO STUDY RNS60’S EFFECT IN A MULTICENTER PHASE II STUDY
OCTOBER 30, 2015
CLINICAL PILOT STUDY OF RNS60 IN ALS ENROLLS FIRST PATIENT
OCTOBER 20, 2014
REVALESIO’S RNS60 DEMONSTRATES PROMISE IN TREATING ALZHEIMER’S DISEASE AND OTHER DEMENTIAS
MARCH 14, 2014
REVALESIO PRESENTS PHASE I HUMAN DATA AT AAAAI